Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost? New research shows that Lecanemab and Donanemab can delay cognitive decline and expand the independence of patients in daily activities.…
Researchers develop low cost, scalable methodology for early dementia detection A new study by researchers from the Regenstrief Institute, Indiana University and Purdue University presents their low-cost, scalable methodology for…
